Problems of anticoagulation within a palliative care setting: An audit of hospice patients taking warfarin

Palliative Medicine

Volumn 11, Issue 4, 1997, Pages 306-312

  Johnson, M J ^a  

^a Hunters Hill Marie Curie Centre   (United Kingdom)

Author keywords

Neoplasms; Palliative care; Thromboembolism; Warfarin

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CANCER; CLINICAL ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG EXCRETION; DRUG MONITORING; GENERAL PRACTICE; HOSPICE; HUMAN; LIVER DISEASE; MEDICAL AUDIT; PALLIATIVE THERAPY; PATIENT CARE; PATIENT MONITORING; RISK; STATISTICAL ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0030801734     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1177/026921639701100407     Document Type: Article

References (26)

1. Trousseau A. Phlegmasia alba dolens. In: Clinique medicale de l'Hotel-Dieu de Paris, Vol. 3. Paris: JB Balliere et Fils, 1865: 654-712.
2. Prandoni P. Deep vein thrombosis and occult cancer. Am Med 1993; 25: 447-50.
3. Rahr HB, Sorensen JV. Venous thromboembolism and cancer. Blood Coag Fibrinolysis 1992; 3: 451-60.
4. Falanga A, Ofosu FA, Delaini F et al. The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions. Blood Coag Fibrinolysis 1994; 5 (suppl 1): S1-S23.
5. Sandier DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thromboses? J R Soc Med 1989; 82: 203-205.
6. Huisman MV, Buller HR, ten Cate JW et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989; 95: 498-502.
7. Lip GYH, Beevers DG, Coope JR. Atrial fibrillation in general and hospital practice. Br Med J 1995; 312: 175-78.
8. Hull R, Raskob G, Hirsch J et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-14.
9. Landefeld CS, Anderson PA, Goodnough LT et al. The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol 1989: 42; 711-18.
10. Colman RW, Rubin R. Disseminated intravascular coagulation due to malignancy. Semin Oncol 1990; 17: 172-86.
11. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metast Rev 1992; 11: 237-48.
12. Gitter MJ, Jaeger TM, Petterson TM et al. Bleeding and thromboembolism during anticoagulant therapy: a population based study at Rochester, Minnesota. Mayo Clin Proc 1995; 70: 725-33.
13. Bick RL. Alterations of haemostasis associated with malignancy: aetiology, pathophysiology, diagnosis and management. Semin Thromb Haemost 1978: 5; 1-26.
14. Clagett GP, Anderson FA Jr, Levine M et al. Prevention of venous thromboembolism. Chest 1992: 102 (suppl): 91S-407S.
15. Levine MN, Hirsh J, Gent M et al. A double blind randomised trial of very low dose warfarin for the prevention of thromboembolism in patients with stage IV breast cancer. Lancet 1994: 343; 886-89.
16. Krauth D, Holden A, Knapic N, Liepman M, Ansell J. Safety and efficacy of long-term oral anticoagulation in cancer patients. Cancer 1987: 59; 983-85.
17. Erricheti AM, Holden A, Anseli J. Management of oral anticoagulant therapy: experience with an anticoagulant clinic. Arch Intern Med 1984; 144: 1966-68.
18. Cantelmo NL, Menzoian JO, Logerfo FW et al. Clinical experience with vena caval filters in high risk cancer patients. Cancer 1982: 50; 341-44.
19. Hull R, Delmore T, Carter C et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-94.
20. Tapson VF, Hull RD. Management of venous thromboembolic disease. The impact of low molecular weight heparin. Clin Chest Med 1995; 16: 281-94.
21. Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost 1994; 72: 330-34.
22. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. Br Med J 1994; 309: 299-304.
23. Lensing AWA, Prins MH, Davidson BL, Hirsch J. Treatment of deep venous thrombosis with low molecular weight heparins. A meta-analysis. Arch Intern Med 1995; 155: 601-607.
24. Monreal M, Lafoz E, Olive A et al. Comparison of subcutaneous unfractionated with low molecular weight heparin (fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
25. Warkentin TE, Levine M, Hirsch J et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-35.
26. Lane DA, Ryan K. Heparin and low molecular weight heparin: is anti-factor Xa activity important? J Lab Clin Med 1989; 114: 331-33.